News headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.7801807128744 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) traded down $0.04 during trading hours on Wednesday, reaching $1.65. 181,400 shares of the company traded hands, compared to its average volume of 156,190. The firm has a market capitalization of $20.12, a PE ratio of -0.67 and a beta of 3.75. Cyclacel Pharmaceuticals has a 52-week low of $1.50 and a 52-week high of $10.90.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.91) EPS for the quarter. sell-side analysts predict that Cyclacel Pharmaceuticals will post -2.25 EPS for the current fiscal year.
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.